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Summary
Background.  —  Very  little  is  known  about  the  costs  of  mitral  regurgitation  (MR)  in  Europe.
Aim. —  To  evaluate  the  cost  of  MR  from  a  French  National  Payer  perspective,  based  on  annual
costs of  surgical  and  non-surgical  patients.
Methods.  —  A  12-month  retrospective  population-based  analysis  of  patient  demographics,  out-
comes and  acute  hospital  and  post-discharge  resource  utilizations,  extracted  from  the  2009Pharmacology French Medical  Information  System.
Results.  —  A  total  of  19,868  patients  with  MR  were  identiﬁed.  Surgical  group  (n  =  4099):  index
hospitalization  length  of  stay  (LOS),  17  ±  14.7  days;  patients  discharged  to  rehabilitation,
72% (LOS  23  ±  16  days);  12-month  rehospitalization  rate,  25%;  total  cost  per  surgical  patient,
D 24,871  ±  13,940  (ranging  from  D  21,970  ±  11,787  for  mitral  valve  repair  [n  =  2567,  62.6%]
Abbreviations: HF, heart failure; ICD, International Classiﬁcation of Diseases; ICU, intensive care unit; LOS, length of stay; LVD, left
entricular dysfunction; MR, mitral regurgitation; PMSI, programme de médicalisation des systèmes d’information.
∗ Corresponding author. Clinique cardiologique et des maladies vasculaires, institut du thorax et du système nerveux, boulevard Jacques-
onod, 44093 Nantes Cedex 1, France.
E-mail address: jeannoel.trochu@chu-nantes.fr (J.-N. Trochu).
http://dx.doi.org/10.1016/j.acvd.2014.09.008
875-2136/© 2014 Elsevier Masson SAS. All rights reserved.
Cost  of  mitral  valve  regurgitation  89
to  D  29,732  ±  15,796  for  mitral  valve  replacement).  Non-surgical  group  (n  =  15,769):  number
of hospitalizations  over  12  months,  3.1  ±  1.5  (LOS  23.5  ±  20.4  days);  admitted  to  rehabilita-
tion, 24%  (LOS  38.8  ±  37.6  days);  total  cost  per  patient,  D  12,177  ±  10,913  (varying  between
D 9957  ±  9080  and  D  13,538  ±  11,692  for  those  without  and  with  heart  failure  [HF],  respec-
tively). The  total  observed  cost  for  19,868  MR  patients  over  12  months  was  D  292.8  million:
surgical group,  D  100.8  million;  medical  group  D  192.0  million.  Patients  with  MR  and  HF  who
were managed  medically  consumed  45%  (D  132.3  million)  of  the  overall  annual  cost  of  MR.
Conclusion.  —  The  costs  of  care  associated  with  MR  are  highly  heterogeneous.  There  are  signif-
icant differences  in  costs  and  resources  used  between  the  surgical  and  medical  MR  subgroups,
with further  differences  depending  on  type  of  surgery  and  presence  of  HF.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  La  connaissance  du  coût  médico-économique  de  l’insufﬁsance  mitrale  reste  très
limitée en  Europe.
Objectif.  —  Évaluer  le  coût  de  l’IM  en  se  basant  sur  l’étude  des  coûts  annuels  rattachés  à  la
prise en  charge  médicale  des  patients  opérés  et  non  opérés.
Méthodes.  —  Il  s’agit  d’une  étude  rétrospective  qui  a  recueilli  à  partir  des  données  du  PMSI
de 2009  et  un  suivi  de  12  mois  les  données  démographiques,  les  événements  cliniques,  les
hospitalisations  non  programmées  et  l’utilisation  des  ressources  médicales  des  patients  ayant
un diagnostic  principal  ou  secondaire  d’insufﬁsance  mitrale.
Résultats.  —  Dix-neuf  mille  huit  cent  soixante-huit  patients  avec  IM  ont  été  identiﬁés.  Groupe
chirurgical  (n  =  4099)  :  la  durée  de  l’hospitalisation  index  (LOS)  était  de  17  ±  14,7  jours  ;  72  %
des patients  étaient  ensuite  hospitalisés  en  centre  de  réadaptation  (LOS  23  ±  16  jours)  ;  le
taux de  réhospitalisations  à  12  mois  était  de  25  %  ;  le  coût  total  moyen  par  patient  chirurgi-
cal était  de  24  871  ±  13  940  D  ,  allant  de  21  970  ±  11  787  D  pour  la  réparation  valvulaire  mitrale
(n =  2567,  62,6  %)  à  29  732  ±  15  796  D  pour  le  remplacement  valvulaire.  Groupe  non  chirurgi-
cal (n  =  15  769)  :  les  patients  ont  été  hospitalisés  en  moyenne  3,1  ±  1,5  fois  sur  une  période
de 12  mois  (LOS  23,5  ±  20,4  jours)  ;  24  %  ont  été  admis  dans  un  centre  de  réadaptation  (LOS
38,8 ±  37,6  jours)  ;  le  coût  total  moyen  par  patient  était  de  12  177  ±  10  913  D  ,  variant  entre
9957 ±  9080  D  à  13  538  ±  11  692  D  respectivement  selon  la  présence  ou  l’absence  d’insufﬁsance
cardiaque.  Le  coût  total  des  19  868  patients  avec  insufﬁsance  mitrale  pendant  12  mois  était  de
292,8 millions  :  100,8  millions  D  pour  le  groupe  chirurgical  et  192,0  millions  D  pour  le  groupe
médical. Les  patient  avec  IM  et  insufﬁsance  cardiaque  pris  en  charge  médicalement  consom-
maient 45  %  (132,3  millions  D  )  du  coût  total  annuel  rattaché  à  l’insufﬁsance  mitrale.
Conclusion.  —  Les  coûts  médico-économiques  et  l’utilisation  des  ressources  médicales  associés
à l’insufﬁsance  mitrale  sont  très  hétérogènes  :  des  différences  signiﬁcatives  existent  entre  les
sous-groupes  des  patients  opérés  et  les  patients  traités  médicalement,  avec  également  des
différences  selon  le  type  de  chirurgie  et  la  présence  d’une  insufﬁsance  cardiaque.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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The  exact  incidence  and  prevalence  of  mitral  regurgita-
tion  (MR)  is  unknown,  but  it  probably  exceeds  ﬁve  million
worldwide  [1,2];  MR  is  the  second  most  common  type
of  heart  valve  disease  requiring  surgery  in  Europe  [3].
The  condition  is  often  associated  with  heart  failure  (HF),
one  of  the  most  common  cardiovascular  disorders  world-
wide,  and  one  that  poses  a  signiﬁcant  economic  burden
[4—6].  In  the  USA,  the  2010  estimated  annual  cost  of
HF  was  $39.2  billion,  approximately  2%  of  the  total  USA
healthcare  budget  [4].  The  main  cost  drivers  of  HF  are
hospitalization,  nursing  home,  home  healthcare  and  med-
ications  [4].  Hospitalizations  account  for  approximately
g
i
u0%  of  the  total  HF  cost  in  the  USA,  reaching  82%
hen  rehabilitations  and  long-term  hospitalizations  are  also
onsidered  [4].
In 2009,  the  therapeutic  options  available  for  the  treat-
ent  of  MR  included  medical  management  or  a  surgical
pproach  (repair  or  replacement).  The  recent  introduction
f  MitraClip®, the  ﬁrst  percutaneous  mitral  valve  repair
evice,  provides  a third  therapeutic  option  for  severe  MR
atients  [7]. A  growing  body  of  evidence  supports  the
ncreased  uptake  of  this  new  therapy  [8—15].  Consequently,
he  2012  European  Society  of  Cardiology  guidelines  sug-
ested  the  use  of  percutaneous  repair  in  patients  with  an
ndication  for  valve  surgery,  but  judged  inoperable  or  at
nacceptably  high  surgical  risk  [16,17].
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Very  little  is  known  about  the  costs  of  MR  in  Europe.
s  hospital  stays  account  for  most  of  the  resources  used
o  manage  MR,  it  is  possible  to  assess  the  burden  of  MR
rom  national  hospital  statistics,  based  on  diagnosis-related
roups.  Thus,  in  the  context  of  the  development  of  a
ercutaneous  approach  for  the  treatment  of  MR  and  the  per-
pective  of  a  cost-efﬁcacy  evaluation,  the  objective  of  this
tudy  was  to  assess  the  hospital  costs  of  MR  from  a French
ational  payer  perspective.
ethods
irect  costs  were  extracted  from  the  French  Medical  Infor-
ation  System  (programme  de  médicalisation  des  systèmes
’information  [PMSI]),  a  national  prospective  database  of
he  activity  of  all  public  and  private  hospitals.  Diagnosis-
elated  groups  are  derived  from  standardized  discharge
eports  following  hospital  stays.  Diagnoses  are  coded  using
he  International  Classiﬁcation  of  Diseases,  10th  revision
ICD-10),  as  either  primary  or  associated  diagnoses  [18]  (e.g.
eft  ventricular  dysfunction  [LVD]  is  coded  by  a  unique  code,
501).  Therapeutic  procedures  are  extensively  coded  using
he  Classiﬁcation  commune  des  actes  médicaux  (CCAM),
 national  standardized  medical  procedures  classiﬁcation
19].  As  a  patient  may  have  several  hospital  stays,  each
atient  is  identiﬁed  using  a  unique  anonymous  number  cal-
ulated  from  their  social  security  number,  date  of  birth  and
ex.  Because  all  discharge  reports  are  compulsory  and  are
he  basis  of  hospital  funding,  the  PMSI  instrument  represents
 unique  exhaustive  database  of  patients  [20].
atient identiﬁcation
ata  for  MR  patients  with  a  follow-up  period  of  12  months
ere  extracted  from  the  2009  PMSI  database  and  divided
nto  two  groups,  deﬁned  by  their  therapeutic  management
s  surgical  or  non-surgical.
urgical  patients
he  population  undergoing  surgery  was  extracted  based  on
ospitalization  data  of  patients  diagnosed  with  MR  (pri-
ary  or  secondary  diagnosis),  using  ﬁve  related  ICD-10
odes:  I340,  I348,  I349,  I511,  I390.  Thus,  this  surgical  group
ncluded  all  mitral  valve  surgeries,  single  or  associated
ith  coronary  revascularizations  or  multiple  valve  repairs
r  replacements.
on-surgical  patients
he  non-surgery  population  was  extracted  based  on  MR  hos-
italizations  identiﬁed  by  the  dedicated  ICD-10  code  (I340).
wo  subgroups  were  identiﬁed  with  and  without  HF  or  left
entricular  failure  according  to  the  following  ﬁve  ICD-10
odes:  I110,  I420,  I500,  I501  and  I509.
As  the  objective  was  to  capture  costs  linked  to  MR  as
he  main  diagnosis  for  hospitalization,  patient  data  were
elected  on  the  basis  of  the  following  criteria:  age  >  50  years;
o  history  of  mitral  valve  surgery  in  the  past  two  years;
o  surgical  management  of  mitral  valve  disease  during  the
ears  of  recruitment  and  follow-up;  and  a  minimum  of  two
ospitalizations  during  2009.
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ata collection
ata  were  extracted  from  2009  and  2010,  and  included
atient  demographics  (sex,  age,  co-morbidities),  mortality,
ischarge  location  and  acute  hospital  resource  utilizations
number  of  hospitalizations,  length  of  stay  [LOS],  number
f  intensive  care  unit  [ICU]  days  [i.e.  ICU  itself,  resusci-
ation  ward  or  continuous  monitoring]  and  hospitalization
harges).  Post-discharge  resource  utilizations  were  also  col-
ected  (rehospitalization  rates  and  charges,  rehabilitation
ates  and  charges).
tatistical analysis
ata  are  expressed  as  mean  ±  standard  deviation  or  number
percentage)  as  appropriate.  Unit  costs  were  expressed  in
uro-2009  values  and  were  derived  according  to  the  French
ational  Payer  perspective  from  published  national  tariffs
rom  the  French  National  Sick  Fund  [21]  for  descriptive  sta-
istical  analyses,  including  distribution  ranges.
esults
atient demographics
n  total,  19,868  patients  with  MR  were  identiﬁed:  4099
nderwent  a  surgical  mitral  valve  intervention  and  15,769
ere  treated  by  non-surgical  means.
The  surgical  group  was  subdivided  according  to  the
urgical  intervention  (valve  repair  or  valve  replacement)
Table  1).  Patients  were  predominantly  male  (62%),  with  a
ean  age  of  65  ±  14  years.  Co-morbidities  included  HF  (15%
f  surgical  patients),  hypertension  (35%),  diabetes  (11%)  and
enal  failure  (6%).
The  non-surgical  group  was  subdivided  depending  on  the
resence  of  HF,  which  was  reported  in  62%  of  patients
Table  1).  Patients  were  predominantly  male  (53%),  with  a
ean  age  of  76  ±  10  years.  Co-morbidities  included  LVD  (46%
f  non-surgical  patients),  hypertension  (72%),  diabetes  (29%)
nd  renal  failure  (29%).
ndex hospital resource utilization
ver  12  months,  the  mean  LOS  in  the  surgical  group  was
7  ±  14.7  days  and  in-hospital  mortality  reached  6.6%  (rang-
ng  from  3.4%  to  12.0%)  (Table  2). In  the  non-surgical
roup,  the  mean  number  of  hospitalizations  was  3.1  ±  1.5
range  2.8  ±  1.2  to  3.3  ±  1.7),  with  a  mean  annual  LOS  of
3.5  ±  20.4  days;  in-hospital  mortality  was  11.4%  (Table  2).
Utilization  of  hospital  resources  yielded  a  total  mean
ospitalization  cost  of  D  19,863  ±  11,571  per  patient  in  the
urgical  group,  including  a  mean  ICU  cost  of  D  4728  ±  8490,
epresenting  a  total  cost  of  around  D  80.6  million.  This
ncluded  the  cost  of  the  devices  (valves  and  annulus)  used
n  all  interventions.  In  the  surgical  subgroup,  the  index  hos-
italization  was  mainly  related  to  mitral  valve  repair  (63%);
lmost  25  patients  underwent  a  combined  procedure  (repair
nd  replacement).  The  decile  distribution  of  these  patients
excluding  device  costs)  showed  that  the  mean  cost  for
he  index  hospitalization  (excluding  device  costs)  increased
rom  D  8900  for  the  1st  decile  to  D  23,912  for  the  9th
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Table  1  Patient  demographics  in  surgical  and  non-surgical  patients  with  mitral  regurgitation.
Surgical  patients  Repair
(n  =  2567)
Replacement
(n =  1532)
Total
(n  =  4099)
Men  68  52  62
Age  (years)  64  ±  14  66  ±  14  65  ±  14
Heart  failure  308  (12)  306  (20)  614  (15)
Hypertension  878  (34)  545  (36)  1423  (35)
Diabetes  207  (8) 228  (15) 435  (11)
Renal  failure 134  (5) 129  (8) 263  (6)
Non-surgical  patients With  heart  failure
(n =  9774)
Without  heart  failure
(n  =  5995)
Total
(n  =  15,769)
Men  54  53  53
Age  (years)  77  ±  10  74  ±  10  76  ±  10
LVD  5269  (54)  2041  (34)  7310  (46)
Hypertension  7099  (73)  4300  (72)  11,399  (72)
Diabetes  3057  (31)  1524  (25)  4581  (29)
Renal  failure  3482  (36)  1021  (17)  4503  (29)
Data are %, number (%) or mean ± standard deviation. LVD: left ventricular dysfunction, deﬁned as ICD-10 code I501.
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Rdecile  and  D  42,532  for  the  10th  decile.  In  the  non-surgical
group,  the  total  mean  hospitalization  cost  per  patient  was
D  10,398  ±  8867,  representing  a  total  cost  of  nearly  D  163.9
million.
Rehabilitation resource use
In  the  surgical  group,  72%  of  patients  were  discharged  to  a
rehabilitation  facility  within  12  months  and  were  admitted
a  mean  1.3  ±  0.9  times,  with  a  mean  LOS  of  23  ±  16  days  for
the  ﬁrst  stay,  at  a  mean  cost  of  D  5253  ±  3551  (Table  3).  In
the  non-surgical  group,  only  24%  of  patients  were  admitted
t
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Table  2  Hospital  resource  utilization  per  surgical  and  non-sur
Surgical  patients  Repair
(n  =  2567)
LOS  (days)  15  ±  12.5  
In-hospital  mortalitya 89  (3.4)  
Costs  (D  )  12,749  ±  3846  
Additional  cost  from  ICU  (D  )  3809  ±  7535  
Additional  cost  from  devices
(valves  and  annulus)  (D  )
700  ±  0  
Total  hospitalization  cost  (D  )  19,158  ±  10,089  
Non-surgical  patients  With  heart  failure
(n  =  9774)
Number  of  hospitalization  stays
after  12  months
3.3  ±  1.7  
LOS  (days)  28  ±  22.1  
Mortality  over  12  months  1474  (15.1)  
Total  hospitalization  cost  (D  )  11,430  ±  9394  
Data are mean ± standard deviation or number (%). ICU: intensive care
a Mortality is linked to the ﬁrst stay whatever its duration below or abo  a  rehabilitation  facility,  but  with  a  slightly  longer
ean  LOS  of  38.8  ±  37.6  days  and  a  higher  mean  cost  of
 7525  ±  7583  (Table  3).
ehospitalization resource utilization in the
urgical subgroup
ehospitalization  resource  utilization  (excluding  rehabili-
ation)  is  presented  for  the  4099  surgical  patients.  The
bserved  rehospitalizations  occurred  within  12  months
fter  the  index  hospitalization:  a  total  of  1025  patients
nderwent  cardiovascular  rehospitalizations,  representing
gical  patient  with  mitral  regurgitation.
Replacement
(n  =  1532)
Total
(n  =  4099)
21  ±  17.2  17  ±  14.7
184  (12.0)  273  (6.6)
14,849  ±  5132  13,534  ±  4487
6268  ±  9696  4728  ±  8490
2600  ±  0  1410  ±  0
23,718  ±  13,218  19,863  ±  11,571
Without  heart  failure
(n  =  5995)
Total
(n  =  15,769)
2.8  ±  1.2  3.1  ±  1.5
16.6  ±  15  23.5  ±  20.4
339  (5.6)  1813  (11.4)
8715  ±  7640  10,398  ±  8867
 unit; LOS: length of stay.
ove 30 days.
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Table  3  Rehabilitation  resource  utilization  per  surgical  and  non-surgical  patient  with  mitral  regurgitation.
Surgical  patients  Repair
(n  =  2567)
Replacement
(n  =  1532)
Total
(n = 4099)
Discharge  to  rehabilitation  1926  (75)  1023  (66)  2949  (72)
LOS  of  ﬁrst  rehabilitation  (days)  23  ±  15  24  ±  17.2  23  ±  16
Number  of  admissions  per  patient  1.3  ±  0.8  1.4  ±  1.2  1.3  ±  0.9
Cost  (D  )  4936  ±  2637  5849  ±  4768  5253  ±  3551
Non-surgical  patients With  heart  failure
(n =  9774)
Without  heart  failure
(n  =  5995)
Total
(n = 15,769)
Admitted  patients  2488  (25)  1239  (20)  3727  (24)
Number  of  admissions 3772  1673  5445
LOS  (days) 40.9  ±  40.5 34.5  ±  30.3 38.8  ±  37.6
Cost  (D  )  8280  ±  8466  6009  ±  5065  7525  ±  7583
Data are number, number (%) or mean ± standard deviation. LOS: length of stay.
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1 rehospitalization  rate  of  25%.  All  cardiac  hospitalizations
ere  considered  (1667  hospital  stays;  Table  4).  When  con-
idering  reasons  for  hospital  stay,  53  (3.2%)  were  related
o  valvular  surgery,  78  (4.7%)  to  coronary  artery  disease
angioplasty,  stent  or  acute  coronary  syndrome),  77  (4.6%)  to
ndocarditis,  505  (30.2%)  to  arrhythmias  and  electrophysio-
ogical  disorders,  314  (18.8%)  to  heart  failure  and  74  (4.4%)
o  same-day  discharge  hospitalization.  The  mean  LOS  per
atient  was  10.4  ±  16.5  days  and  the  mortality  rate  over  the
otal  population  was  1.1%  (Table  4).  In  total,  33%  of  patients
equired  two  or  more  rehospitalizations  (Fig.  1).  The  mean
ehospitalization  cost  for  one  stay  occurring  12  months  after
urgery  was  D  3324  ±  4722  (Table  4).
otal resource cost
he  total  resource  cost  was  calculated  for  the  total  popu-
ation  in  each  group  (n  =  4099  surgical  patients;  n  =  15,769
on-surgical  patients).  In  the  surgical  group,  the  mean
ost  of  the  index  hospitalization  was  D  19,673  ±  11,571
er  patient,  the  mean  ﬁrst  rehabilitation  stay  cost
as  D  5253  ±  3551  and  mean  12-month  rehospitalization
osts  were  D  5675  ±  9030,  giving  a  total  mean  cost  of
 24,871  ±  13,940  per  patient  (Table  5  and  Fig.  2).  The  total
nnual  cost  for  all  surgical  MR  patients  treated  between
009  and  2010  was  D  100.8  million.  The  decile  distribution
howed  that  the  average  annual  cost  for  hospitalizations  in
he  repair  group  of  surgical  patients  ranged  from  D  9201  per
c
w
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Table  4  Rehospitalization  resource  utilization  per  surgical  pa
Repair
(n  =  2567)
Number  of  rehospitalization  stays  865  (33.6)  
LOS  per  patient  (days)  9  ±  14.3  
Mortality  13  (0.5)  
Cost  per  rehospitalization  stay  (D  )  2781  ±  3745  
Data are number (%) or mean ± standard deviation. LOS: length of stayigure 1. Number of rehospitalizations in the surviving surgical
atients during the 12 months after surgery.
atient  for  the  1st  decile  to  D  27,800  for  the  9th  decile  and
 46,915  for  the  10th  decile.  The  average  cost  for  those  in
he  replacement  group  ranged  from  D  10,458  for  the  1st
ecile  to  D  40,243  for  the  9th  decile  and  D  66,963  for  the
0th  decile.
In  the  non-surgical  group,  the  total  mean  resource
ost  of  hospitalizations  and  rehabilitations  over  12  months
as  D  12,177  ±  10,913  per  patient,  representing  a  total  of
 192.0  million  (D  163.9  million  for  hospitalizations,  D  28
tient  during  12-month  follow-up  after  surgery.
Replacement
(n =  1532)
Total
(n =  4099)
802  (52.3)  1667  (40)
12.5  ±  18.5  10.4  ±  16.5
32  (2.1)  45  (1.1)
3960  ±  5587  3324  ±  4722
.
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Table  5  Resource  per  surgical  and  non-surgical  patient  with  mitral  regurgitation.
Surgical  patients  Repair
(n  =  2567)
Replacement
(n  =  1532)
Total
(n  =  4099)
Index  hospitalization  cost  per  patient  (D  ) 19,158  ±  10,089  23,718  ±  13,222  19,863  ±  11,571
Rehabilitation  cost  (D  )  4936  ±  2637  5849  ±  4768  5253  ±  3551
Rehospitalization  cost  per  patient  (D  ) 4678  ±  7660 6844  ±  10,295  5675  ±  9030
Total  cost  per  patient  (D  ) 21,970  ±  11,787 29,732  ±  15,796 24,871  ±  13,940
Non-surgical  patients  With  heart  failure
(n =  9774)
Without  heart  failure
(n  =  5995)
Total
(n =  15,769)
Index  hospitalization  costs  (D  ) 11,431  ±  9394 8715  ±  7640 10,398  ±  8867
Rehabilitation  costs  (D  ) 8280  ±  8466 6009  ±  5065 7525  ±  7584
Total  cost  (D  )  13,538  ±  11,692  9957  ±  9080  12,177  ±  10,913
(
s
e
D
p
H
s
w
c
i
t
p
l
T
gData are mean ± standard deviation.
million  for  rehabilitation)  (Table  5  and  Fig.  3).  The  decile
distribution  showed  that  the  average  annual  cost  for  hospi-
talizations  ranged  from  D  1610  per  patient  for  the  1st  decile
to  D  15,082  for  the  9th  decile  and  D  25,633  for  the  10th
decile  of  the  population  without  HF,  and  from  D  14,257  for
the  1st  decile  to  D  18,777  for  the  9th  decile  and  D  32,061
for  the  10th  decile  for  patients  with  HF.
It  is  also  worth  noting  that  patients  in  the  10th  decile  of
acute  care  hospitalizations  were  admitted  a  mean  4.8  times
per  year  (LOS  11.1  days).  In  the  10th  decile  of  rehabilitation
care,  patients  were  admitted  a  mean  2.8  times  per  year  (LOS
117.9  days).
DiscussionThis  study  demonstrates  high  heterogeneity  in  the  costs
of  care  associated  with  MR  during  a  12-month  follow-
up,  with  signiﬁcant  cost  differences  between  surgical
N
v
c
f
Figure 2. Cumulative total cost of surgical patients.D  24,871  ±  13,940)  and  medical  (D  12,177  ±  10,913)  MR
ubgroups.  Within  each  subgroup,  there  were  differ-
nces  in  cost  depending  on  the  type  of  surgery  (repair,
 21,970  ±  11,787;  replacement,  D  29,732  ±  15,796)  and
resence  (D  13,538  ±  11,692)  or  absence  (D  9957  ±  9080)  of
F  for  medical  MR.  The  overall  annual  cost  of  mitral  valve
urgery  (n  =  4099  patients)  was  around  D  100  million  but
as  as  high  as  D  192  million  for  patients  managed  medi-
ally  (n  =  15,769).  The  aetiology  of  MR  was  not  available
n  the  PMSI  database,  but  probably  differed  between  the
wo  groups.  The  main  aetiology  of  MR  is  usually  organic  in
atients  referred  for  surgery,  while  functional  MR  is  most
ikely  to  be  the  main  cause  of  MR  in  the  non-surgical  group.
hus,  the  clinical  status  of  patients  in  the  non-surgical
roup  appeared  to  be  worse  than  in  the  surgical  group.
on-surgical  patients  were  older  (mean  age  76  ±  10  years
s  65  ±  14  years,  respectively),  with  a greater  prevalence  of
o-morbidities,  such  as  HF,  hypertension,  diabetes  and  renal
ailure.  In  addition,  62%  of  non-surgical  patients  had  HF
94  J.-N.  Trochu  et  al.
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pigure 3. Cumulative total cost of non-surgical patients.
ompared  with  15%  in  the  surgical  group.  Also,  the
on-surgical  population  was  similar  to  that  described
n  the  literature,  where  the  most  frequently  observed
o-morbidities  for  MR  are  cardiovascular-related  condi-
ions  (hypertension,  dyslipidaemia,  diabetes)  and  chronic
bstructive  pulmonary  disease  [3].  Functional  MR  is  often
ssociated  with  and  is  a  consequence  of  HF,  one  of  the  most
ommon  cardiovascular  disorders  worldwide  [4]. Hence,
he  present  study  also  illustrates  the  additional  economic
mpact  of  HF  in  patients  diagnosed  with  MR.
urgical group
he  reported  mortality  associated  with  the  index  hospi-
alization  in  the  surgical  group  was  6.6%,  ranging  from
.4%  in  repair  interventions  up  to  12.0%  in  replacements.
hese  ﬁndings  are  consistent  with  the  literature,  in  terms  of
pidemiological  data  and  survival  rates  of  surgical  interven-
ions  on  the  mitral  valve;  the  periprocedural  mortality  rates
escribed  in  surgical  series  vary  between  2.1%  and  11.0%  in
atients  with  depressed  left  ventricular  function,  and  can  be
s  high  as  25%  in  very-high-risk  or  elderly  patients  [22—24].
Surgical  cost  is  dependent  on  the  selected  technique  and
s  reported  to  be  signiﬁcantly  higher  for  mitral  valve  replace-
ent  than  for  mitral  valve  repair  [25].  The  mean  LOS  was
7  ±  14.7  days,  including  days  in  the  ICU.  By  adding  the
ost  of  the  hospital  and  the  cost  of  the  device  (invoiced
n  addition  to  the  stay),  we  estimated  that  an  average  stay
as  D  19,863  ±  11,571.  In  a  study  in  the  USA,  the  main  cost
rivers  (direct  and  indirect)  of  mitral  valve  surgery  were  ICU
tay  (15%)  and  medical  supplies  (15%),  general  ward  stay
14%),  perfusion  (12%),  pharmacy  (8%)  and  operating  room
8%)  [26].
A signiﬁcant  proportion  of  patients  (72%)  were  discharged
o  a  rehabilitation  facility,  incurring  an  additional  mean
ost  of  D  5253  ±  3551.  In  addition,  25%  of  the  4099  surviv-
ng  patients  were  rehospitalized  in  the  12  months  following
he  index  hospitalization,  incurring  an  additional  mean  cost
t
r
H
aer  stay  of  D  3324  ±  4722.  Thus,  although  the  index  hospi-
alization  for  surgical  intervention  represented  around  80%
f  the  total  12-month  cost  for  a  surgical  patient,  costs
f  rehabilitation  and  subsequent  hospitalizations  played  an
mportant  role  in  the  total  mean  burden,  estimated  to  be
 24,871  ±  13,940  per  patient.  It  is  noteworthy  that  costs  for
atients  in  the  10th  decile  reached  D  46,915  for  the  repair
roup  and  D  66,963  for  patients  who  underwent  replace-
ent.
on-surgical group
n  our  non-surgical  patients,  a  mean  3.1  ±  1.5  hospital  stays
n  acute  care  were  observed  over  12  months,  with  a  mean
OS  of  23.5  ±  20.4  days  and  a  mean  cost  of  D  10,398  ±  8867.
verall,  24%  of  these  patients  were  admitted  to  a  reha-
ilitation  facility  within  12  months,  with  a  mean  LOS  of
8.8  ±  37.6  days  and  a  mean  cost  of  D  7525  ±  7583.  The
ean  annual  cost  in  the  non-surgical  subgroup,  includ-
ng  acute  and  rehabilitation  hospitalization  stays,  was
 12,177  ±  10,913,  ranging  from  D  9957  ±  9080  for  patients
ithout  HF  to  D  13,538  ±  11,692  for  patients  with  HF.  The
ecile  distribution  of  these  patients  showed  that  the  mean
nnual  cost  for  hospitalizations  was  D  25,633  for  the  10th
ecile  of  patients  without  HF  and  D  32,061  for  patients  with
F.
eart failure
eart  failure  was  found  in  15%  of  surgical  patients  and
2%  of  non-surgical  patients.  While  HF  is  a  consequence
f  organic  MR,  LVD  leading  to  HF  is  known  as  the  main
ause  of  functional  MR,  which  probably  accounts  for  a  large
roportion  of  medically-managed  patients.  However,  func-
ional  MR  further  increases  HF  symptoms  and  left  ventricular
emodelling,  and  worsens  the  prognosis  of  patients  with
F.  As  previously  described,  the  main  cost  drivers  of  HF
re  hospitalization,  nursing  home,  home  healthcare  and
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medications  [4].  Hospitalizations  account  for  approximately
60%  of  total  HF  costs  in  the  USA  [4].  Cost  analysis  using  the
PMSI  database,  which  allows  analysis  of  both  hospitaliza-
tions  and  rehabilitation  costs,  showed  that  the  presence  of
HF  imposes  a  36%  higher  burden  in  terms  of  cost  for  the
non-surgical  group.
Perspectives for new therapeutic options
Considering  the  economic  burden  of  MR,  this  study  under-
scores  the  potential  beneﬁt  of  earlier  recognition,  adequate
evaluation  and  follow-up  of  functional  and  organic  MR,  and
strongly  suggests  the  importance  of  earlier  referral  to  spe-
cialized  heart  valve  clinics  to  improve  the  quality  of  care
[27].
The  current  therapeutic  options  for  MR  include  medical
management,  surgical  repair  or  replacement  [1,17].  Nev-
ertheless  some  limitations  are  observed  for  both  medical
and  surgical  approaches:  no  medications  treat  MR—they  only
manage  patients’  symptoms  and  decrease  left  ventricular
remodelling;  and  there  is  no  medical  therapy  indicated  for
asymptomatic  patients  with  chronic  MR.  Regarding  surgi-
cal  management  of  MR,  many  patients  are  not  considered
appropriate  candidates  for  mitral  valve  surgery;  up  to  50%
of  patients  with  severe  symptomatic  MR  are  not  referred  for
surgery,  even  if  a  surgical  indication  exists.  The  reasons  for
denying  surgery  include  impaired  left  ventricular  ejection
fraction,  a  high  operative  risk,  multiple  co-morbidities  and
advanced  age  [3,28].
When  medically  required  and  technically  practicable,
mitral  valve  repair  should  be  considered  as  the  ﬁrst-line
strategy  in  MR  patients  [17,29].  However,  the  European
Society  of  Cardiology  [17]  recently  published  that  the  role
of  isolated  mitral  valve  surgery  in  patients  with  severe
functional  MR  and  severe  left  ventricular  systolic  dysfunc-
tion  who  cannot  be  revascularized  or  have  non-ischaemic
cardiomyopathy  is  questionable,  and  in  most  patients  con-
ventional  medical  and  device  therapy  are  preferred.  In
patients  with  an  indication  for  valve  repair,  but  who  are
judged  inoperable  or  at  unacceptably  high  surgical  risk,  per-
cutaneous  edge-to-edge  repair  may  be  considered,  in  order
to  improve  symptoms  [16].  The  results  of  our  study  suggest
that  the  highest  economic  burden  for  the  treatment  of  MR
patients  arises  from  long  and  frequent  hospitalizations  and
rehabilitation  costs.  The  percutaneous  edge-to-edge  repair
has  demonstrated  a  signiﬁcant  reduction  in  post-procedural
LOS  (2.6  days  vs  7.5  days  in  a  surgical  control  group)  (EVER-
EST  II  randomized  controlled  trial;  Abbott  Clinical  Report,
on  ﬁle)  and  a  signiﬁcant  reduction  in  length  of  stay:  11  days
(range  seven  to  19  days)  for  surgery  vs  ﬁve  days  (range  four
to  nine  days)  for  percutaneous  mitral  valve  repair  [30].  In
this  context,  the  percutaneous  edge-to-edge  repair  therapy
might  be  considered  an  interesting  therapeutic  approach  for
selected  MR  patients;  its  potential  to  reduce  hospital  costs
should  be  further  investigated  as  part  of  its  economic  value.
Study limitationsAlthough  this  study  included  all  patients  in  France  diag-
nosed  with  MR  who  were  hospitalized  during  the  1-year
duration  of  the  study,  some  limitations  remain.  In  the  non-
surgical  group,  only  patients  with  a  minimum  of  two  hospital
R95
dmissions  in  the  year  of  observation  were  included,  leading
o  an  underestimation  of  the  total  burden.  The  PMSI  instru-
ent  was  initially  developed  for  hospital  funding  arbitration
ased  on  medical  activity,  and  not  for  epidemiological
esearch;  however,  the  recent  improvements,  such  as  the
bility  to  identify  and  observe  resource  use  linked  to  indi-
idual  patients,  open  the  ﬁeld  to  scientiﬁc  research.  The
ifferent  coding  options  for  the  same  clinical  status  or
ntervention  might  lead  to  greater  variability  due  to  cod-
ng  optimization  and  possible  miscoding.  In  our  experience,
hese  coding  errors  occur  in  <  5%  of  cases.  A  limited  number
f  patients  may  beneﬁt  from  hospital  care  provided  at  home.
iven  that  this  represents  < 1%  of  patients,  the  authors  did
ot  consider  these  costs.  Nevertheless,  the  costs  results  are
onsistent  with  those  of  a  recent  cost-effectiveness  study
onducted  in  France  comparing  valve  repair  versus  replace-
ent  [29].
onclusions
his  is  the  ﬁrst  study  to  report  hospital  costs  speciﬁcally
ssociated  with  MR  in  France,  conﬁrming  the  high  bur-
en  of  this  disease.  The  total  observed  annual  cost  was
 292.8  million.  Signiﬁcant  differences  were  observed  in
osts  and  resources  used  between  the  surgical  and  non-
urgical  groups,  and  depending  on  the  type  of  surgery  or
resence  of  HF  within  each  subgroup.  The  awareness  of  MR-
elated  hospitalization  costs  stresses  the  importance  of  early
eferral  of  patients  with  primary  MR,  to  allow  timely  inter-
ention  and  management  of  these  patients  in  heart  valve
linics.  There  is  a  need  for  controlled  trials  in  secondary
R  to  evaluate  the  beneﬁt  of  interventions,  particularly
ercutaneous  techniques  that  have  been  shown  to  be  fea-
ible  with  a relatively  low  risk.  The  possibility  of  improving
he  outcome  of  patients  who  are  currently  not  referred  for
nterventions  may  have  an  important  medical  and  economic
mpact,  given  the  current  economic  burden  of  medically
reated  patients  with  MR.
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